Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Currently, standard wound care practice is suboptimal at assessing wound remodeling and bacterial infection in real-time. An alternative and complimentary means of providing real-time imaging of connective tissue re-modeling and bacterial infection may greatly increase the early detection of infection thus leading to rapid therapeutic intervention. Our new device, PRODIGI(TM), images tissue and bacterial autofluorescence (without agents) and may provide this clinically-important capability.
In preliminary preclinical testing, the investigators have discovered that when wounds are illuminated by violet/blue light, endogenous collagen in the connective tissue matrix emit a characteristic green fluorescent signal, while most pathogenic bacterial species emit a unique red fluorescence signal due to the production of endogenous porphyrins. Therefore, with autofluorescence imaging, no exogenous contrast agents are needed during imaging, making this approach particularly appealing as a diagnostic imaging method for clinical use.
The investigators hypothesize that real-time imaging of tissue autofluorescence signals emanating from endogenous connective tissue (e.g. collagen) and pathogenic bacteria within complex wounds can be used to determine healing status (i.e., collagen re-modeling and wound closure), detect wound bacterial contamination and/or infection that is occult under standard clinical white light evaluation, and guide intervention and wound care.
| Condition |
|---|
|
Surgical Wounds Abdominal Wounds |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
20 patients with wounds resulting from general abdominal surgery will be entered into this trial, based on statistical power-based calculations for sample size determined in collaboration with the UHN Biostatistics Group (assuming one wound per patient).
Inclusion Criteria:
- > 18 years of age
- males and females
- receiving care as in-patient at St. Michael's Hospital
- presenting with abdominal wounds resulting from general surgery with known or unknown infection status.
Exclusion Criteria:
- treatment with an investigational drug within 1 month before study enrolment
- any contra-indication to routine wound care and/or monitoring
- inability to consent
Contacts and Locations| Contact: Ralph S DaCosta, PhD | (416) 581-8645 | rdacosta@uhnresearch.ca |
| Contact: Jo Hoeflock, RN | 416 864-5112 | hoeflokj@smh.ca |
| Canada, Ontario | |
| St. Michael's Hospital | Not yet recruiting |
| Toronto, Ontario, Canada, M5B 1W8 | |
| Contact: Jo Hoeflok, RN 416 864-5112 hoeflokj@smh.ca | |
| Principal Investigator: | Ralph S DaCosta, PhD | University Health Network, Toronto |
More Information
No publications provided
| Responsible Party: | Ralph DaCosta, Principal Investigator, University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT01650571 History of Changes |
| Other Study ID Numbers: | 12-5024-A |
| Study First Received: | July 23, 2012 |
| Last Updated: | July 25, 2012 |
| Health Authority: | Canada: Health Canada |
ClinicalTrials.gov processed this record on May 16, 2013